Menopause and prolactin secreting tumours

Open access


Introduction Prolactinomas without galactorhhea may be considered menopause or not diagnosed. This is a cases series.

Case1. 76-year female with menopause at age of 52 was discovered at 66 yrs with high prolactin and a pituitary micro-nodule. Bromocriptin was continued for 6 years then switched to cabergoline with constant imagery. The patient did not display at all galactorrhea. Osteoporosis was diagnosed at age of 66 with previous 2 fragility fractures.

Case2. 45-year female is known with secondary amenorrhea (without galactorrhea) for the last 7 years being considered menopause. She experienced headaches thus a MRI was performed and found a pituitary tumour of 1.5cm. Low FSH with increased prolactin was revealed. Cabergoline was started. Within 2 months the menses resumed and headache mildly improved. After 3 months prolactin normalised under weekly 2 mg of cabergoline. Periodical prolactin control is necessary as well as a pituitary scan at 6 months.

Case3. 39-year female had a 3 yrs history of secondary amenorrhea. A prolactin of 117ng/mL and a microprolactinoma of 0.77cm were found. Cabergoline was started and progressively increased up to 1.5mg per week. The prolactin quickly normalised up to 8ng/mL within 4 months. She was followed for 2 years and the imagery found a tumour reduction to 0.44cm.

Conclusion Prolactinomas associate a great variety of clinical presentations. They interfere with menopause by mimicking it in cases without galactorrhea. Also a newly diagnosed prolactinoma during menopause needs long term therapy and followed-up for especially for bone safety.

1. Tjörnstrand, A., Gunnarsson, K., Evert, M., Holmberg, E., Ragnarsson, O., Rosé,n T. & Filipsson, N.H. (2014). Incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol .171(4), 519-26. doi: 10.1530/EJE-14-0144.

2. Raappana, A., Koivukangas, J., Ebeling, T. & Pirilä, T. (2010). Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab . 95(9), 4268-75. doi: 10.1210/jc.2010-0537.

3. Fernandez, A., Karavitaki, N. & Wass, J.A. (2010). Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) ;72(3), 377-82. doi: 10.1111/j.1365-2265.2009.03667.x.

4. Schlechte, J.A. (2007). Long-term management of prolactinomas. J Clin Endocrinol Meta. 92(8), 2861-5.

5. Kars, M., Dekker,s O.M., Pereira, A.M. & Romijn, J.A. (2010). Update in prolactinomas. Neth J Med. 68(3), 104-12.

6. Karunakaran, S., Page, R.C. & Wass, J.A. (2001). The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) .54(3),295-300.

7. Naliato, E.C., Violante, A.H., Caldas, D., Farias, M.L., Bussade, I., Lamounier, F.A., Loureiro, C.R., Fontes, R., Schrank, Y., Loures, T. & Colao, A. (2008). Bone density in women with prolactinoma treated with dopamine agonists. Pituitary .11(1),21-8.

8. Vartej, P., Poiana, C. & Vartej, I. (2001). Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol .15(1),43-7.

9. Zhao, Y., Gan, X., Luo, P., He, Q., Guo, Q., Zhang, L., Zhang, X., Zhang X. & Fei Z. (2012). The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol .28(12), 945-8. doi: 10.3109/09513590.2012.683080.

10. Sanfilippo, J.S. (1999). Implications of not treating hyperprolactinemia. J Reprod Med 44(12 Suppl),1111-5.

11. Delemer, B. (2012). MEN1 and pituitary adenomas. Ann Endocrinol (Paris) 73(2), 59-61. doi: 10.1016/j.ando.2012.03.038.

12. Agarwal, S.K., Ozawa, A., Mateo, C.M. & Marx S.J. (2009). The MEN1 gene and pituitary tumours. Horm Res . 71 Suppl 2,131-8. doi: 10.1159/000192450

13. Pekic, S., Stojanovic, M. & Popovic, V. (2015). Contemporary issues in the evaluation and management of pituitary adenomas. Minerva Endocrinol. [Epub ahead of print]

14. Huan, C., Cui, G. & Ren, Z. (2015). The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients. Pak J Pharm Sci . 28(2 Suppl), 713-8.

15. Wang, M., Mou, C., Jiang, M., Han, L., Fan, S., Huan, C., Qu, X., Han, T., Qu, Y. & Xu, G. (2012). The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol .166(5),797-802. doi: 10.1530/EJE-11-1119.

16. Molitch, M.E. (2015). Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol .172(5), R205-13. doi: 10.1530/EJE-14-0848.

17. Molitch, M.E. (2011). Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 25(6),885-96. doi: 10.1016/j.beem.2011.05.011.

18. Verhelst, J. & Abs, R. (2003).Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2(1), 23-32.

19. Malik, S., Hussain, S.Z., Basit, R., Idress N., Habib, A., Zamant, M. & Islam, N. (2014). Demographic characteristics, presentations and treatment outcome of patients with prolactinoma. J Ayub Med Coll Abbottabad . 26(3),269-74.

ARS Medica Tomitana

The Journal of "Ovidius" University of Constanta

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 85 85 10
PDF Downloads 22 22 5